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Background: To evaluate the dose-effect relations for myocardial metabolic disorders after mediastinal radiotherapy
(RT) by performing iodine-123 β-methyl-iodophenyl pentadecanoic acid (I-123 BMIPP) scintigraphy.
Methods: Between 2011 and 2012, we performed I-123 BMIPP scintigraphy for patients with esophageal cancer
before and six months after curative mediastinal RT. Single photon emission computed tomography (SPECT) images
of pre-RT and post-RT were registered into RT dose distributions. The myocardium was contoured, and the regional
RT dose was calculated. Normalization is required to compare pre- and post-RT SPECT images because the uptake
pattern is changed due to the breathing level. Normalization was applied on the mean of SPECT counts in regions
of the myocardium receiving less than 5 Gy. Relative values in each dose region (interval of 5 Gy) were calculated
on the basis of this normalization for each patient. The reduction in the percent of relative values was calculated.
Results: Five patients were enrolled in this study. None of the patients had a past history of cardiac disease. The
left ventricle was partially involved in RT fields in all patients. The patients received RT with median total doses of
60-66 Gy for the primary tumor and metastatic lymph nodes. Concomitant chemotherapy consisting of cisplatin or
nedaplatin and 5-fluorouracil with RT was performed in 4 patients. All patients had reduced uptake corresponding
to RT fields. Dose-effect relations for reduced uptake tended to be observed at 6 months after RT with mean
decreases of 8.96% in regions at 10-15 Gy, 12.6% in regions at 20-25 Gy, 15.6% in regions at 30-35 Gy, 19.0% in
regions at 40-45 Gy and 16.0% in regions at 50-55 Gy.
Conclusions: Dose-effect relations for myocardial metabolic disorders tended to be observed. We may need to
make an effort to reduce high-dose mediastinal RT to the myocardium in RT planning.
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Several studies have revealed that long-term survivors
with Hodgkin’s lymphoma, breast cancer and esophageal
cancer after mediastinal radiotherapy (RT) have RT-
induced heart disease (RIHD) such as pericarditis, myo-
cardial ischemia, cardiomyopathy, heart failure, valvular
abnormalities, or conduction defects [1-5]. RIHD is one
of the late complications that radiation oncologists must* Correspondence: reirei513@hotmail.com
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unless otherwise stated.be aware of. One of the pathological mechanisms of
RIHD is microvascular injury that occurs within several
months of RT [6]. Irradiation to the myocardium causes
damage to the microvasculature, leading to inflamma-
tory and thrombotic changes, capillary loss, focal ische-
mia, and interstitial fibrosis [6,7]. In some past studies,
myocardial perfusion defects corresponding to RT fields
were found by myocardial perfusion scintigraphy [8,9].
The onset of myocardial ischemia is followed by meta-
bolic disorder, left ventricular dysfunction, electrocar-
diographic changes and angina [10]. The main energy
source of the myocardium changes from free fatty acidsral. This is an Open Access article distributed under the terms of the Creative
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our previous study, we reported that reduced uptake
(myocardial metabolic disorder) corresponding to RT
fields was observed mainly in the base of the left ven-
tricle by using scintigraphy with iodine-123 β-methyl-
iodophenyl pentadecanoic acid (I-123 BMIPP), which is
a branched fatty acid analogue that enters myocardial
cells and can show the degree of myocardial fatty acid
metabolism [12]. However, we did not perform I-123
BMIPP scintigraphy before RT as a limitation of that
study.
The purpose of the present study was to evaluate myo-
cardial metabolic disorders corresponding to RT fields
by performing I-123 BMIPP scintigraphy before and
after mediastinal RT. We also evaluated the dose-effect
relations for reduced uptake. We report these results as
a pilot study.
Methods
Patients
Between 2011 and 2012, we performed I-123 BMIPP
scintigraphy for patients with early stage esophageal can-
cer before and six months after curative mediastinal RT.
This study was approved by a local institutional review
board, and all of the patients gave written informed con-
sent before enrolment.
I-123 BMIPP scintigraphy (myocardial fatty acid imaging)
Single photon emission computed tomography (SPECT)
imaging was performed 20 minutes after intravenous ad-
ministration of 111 MBq of I-123 BMIPP (Cardiodine®
Injectable, provided by Nihon Mediphysics Co, Sendai,
Japan), using a dual-detector gamma camera combined
with computed tomography (CT) (Symvia T2, Siemens,
Hoffman Estates, IL). The SPECT scan was performed
with a low-energy, high-resolution collimator, a matrix
of 64 × 64 (pixel size, 3.3 × 3.3 mm) and an acquisition
time of ninety 25-s frames over 360°. The 159 keV
photopeak for I-123 with a 24% window was selected for
data acquisition. No downscatter correction was per-
formed. The SPECT images were reconstructed itera-
tively using 3-dimensional ordered-subsets expectation
maximization with 8 iterations and 5 subsets with a 3D
spatial Gaussian filter (9.6 mm in full width at half
maximum). We performed SPECT/CT in the condition
of expiration to compare with the RT fields more easily
and to detect anatomical locations more clearly.
Radiotherapy
Gross tumor volume was defined as the primary tumor
and nodal metastasis based on a CT scan and positron
emission tomography-CT. If it was difficult to discrimi-
nate the primary tumor on the RT planning CT, the
clips were placed on the proximal and distal sides of theprimary tumor. Initial clinical target volume (CTV) was
defined as the region from the supraclavicular to celiac
lymph nodes. Initial CTV was made small in conside-
ration of the patient’s general condition. Boost CTV was
defined as the primary tumor with a 20-30-mm cranio-
caudal margin and an approximately 5-mm radial mar-
gin and nodal metastasis. Planning target volume was
defined as CTV plus a 5-15-mm margin. The initial
CTV received 40 Gy using parallel-opposed anterior-
posterior fields. The boost CTV received 20-26 Gy using
parallel-oblique fields to avoid the spinal cord. The total
dose was 60-66 Gy. Treatment planning was performed
by CT in all patients, and the dose distribution was
determined by ECLIPSE Varian Medical Systems (Palo
Alto CA) with the analytical anisotropic algorithm. The
dose volume histogram (DVH) of the myocardium was
calculated. By reference to the literature of Feng et al.
[13], the myocardium was contoured. The inner cavity
of the left ventricle was excluded.
Deformable image registration (DIR)
We performed CT separately at the planning for initial
CTV and boost CTV. Basically, although we can add
them with the same planning CT image, it is impossible
to add two dose distributions with different planning CT
images. The deformable image registration (DIR) tech-
nique enables us to make dose accumulation with dose
warping [14-18]. Using dose warping, we created total
dose distribution by adding the initial and boost plans. In
this study, DIR with the region of interest (ROI) technique
implemented in a 3D slicer (Brigham and Women’s
Hospital, Boston, MA) was performed. The DIR algorithm
was B-spline. This algorithm has already been validated
[18]. First, DIR was performed between initial planning
CT (reference image) and boost planning CT (moving
image) to create a transformation using the ROI. The ROI
was basically defined to cover the dose distribution. Then
resultant transformation was applied to the boost dose
distribution to create the deformed boost dose distribu-
tion, which was a warped dose distribution according to
the reference CT image. The accuracy was judged by the
quality of alignment from visual inspection. Finally, we
added the two dose distributions to create total dose
distribution.
Registering SPECT images with RT dose distribution
To quantify post-RT myocardial metabolic disorder in
the myocardium, all SPECT images at pre- and post-RT
and a planning CT image with dose distribution needed
to be defined on the same coordinate space. Automatic
rigid registration with the ROI technique was performed.
The steps consisted of (a) the ROI being basically de-
fined to cover the heart, (b) automatic rigid registration
performed using the ROI to align the two CT images
Figure 1 Evaluation of the relations between radiation dose and
myocardial metabolic disorder. Normalization was applied on the
mean of single photon emission computed tomography counts in
regions of the myocardium receiving less than 5 Gy (red arrow).
Relative values in each dose region (interval of 5 Gy) were calculated
on the basis of this normalization for each patient. The reduction in
the percent of relative values was calculated.
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CT image with perfusion) and judgment of the quality of
alignment from visual inspection, (c) manual registration
performed if adjustment needed and (d) the derived
translations and rotations applied to pre- or post-RT
SPECT perfusion.
Evaluation of the relations between RT dose and
myocardial metabolic disorder
Normalization is required to compare pre- and post-RT
SPECT images because the uptake pattern is changed
due to the breathing level and the circumstance of hun-
ger before I-123 BMIPP scintigraphy. By reference to the
report by Seppenwoolde et al. [19], normalization was
applied on the mean of SPECT counts in the regions of
the myocardium receiving less than 5 Gy, assuming that
RT-induced microvascular injury is not present at this
low dose (Figure 1). The mean of SPECT counts in each
dose region (interval of 5 Gy) was determined, and rela-
tive values in each dose region were calculated on theTable 1 Patient characteristics
Case Age Sex TNM Primary site Smoki
1 75 Male T1bN0M0 Lt +
2 82 Male T1bN0M0 Lt +
3 82 Male T1bN0M0 Mt +
4 73 Male T3N0M0 Mt +
5 73 Male T1bN0M0 Lt +
Abbreviations: HT hypertension, DM diabetes, HL hyperlipidemia, RT radiation, Lt low
CDDP cisplatin, 5-FU 5-fluorouracil.basis of this normalization for each patient. This process
was performed at the I-123 BMIPP examinations of pre-
and post-RT. The reduction in the percent of relative
values at pre- and post-RT SPECT was calculated in
each dose region.
Cardiac examination
Changes in brain natriuretic peptide (BNP) level, electro-
cardiogram (ECG) and pericardial effusion were deter-
mined after RT in all patients. We investigated whether
reduced uptake reflected those changes.
Results
Five patients were enrolled in this study. None of the pa-
tients had a past history of cardiac disease. The left ven-
tricle was partially involved in RT fields in all patients.
Patients’ characteristics are shown in Table 1. Conco-
mitant chemotherapy consisting of 2 cycles of cisplatin
or nedaplatin and 5-fluorouracil (5-FU) with RT was
performed in 4 patients. DVHs of the myocardium for 5
patients are shown in Figure 2. The means of V10, V20,
V30, V40 and V50 of the myocardium were about 30.6%,
25.0%, 21.2%, 14.9% and 4.65%, respectively. V30 of the
myocardium in two patients (Case 4 and Case 5) was
more than 30%.
All patients had reduced uptake corresponding to RT
fields. The results of dose-effect relations for myocardial
metabolic disorder are shown in Figure 3. Dose-effect
relations for reduced uptake tended to be observed at 6
months after RT with mean decreases of 8.96% in re-
gions at 10-15 Gy, 12.6% in regions at 20-25 Gy, 15.6%
in regions at 30-35 Gy, 19.0% in regions at 40-45 Gy and
16.0% in regions at 50-55 Gy. From visual inspection,
reduced uptake corresponding to RT fields was distinct
in Case 4 and Case 5. Images of Case 5 are shown in
Figure 4. In this case, reduced uptake corresponding to
anterior-posterior fields (40 Gy line) was observed.
The results of cardiac examinations are shown in
Table 2. None of the patients had symptoms when they
underwent I-123 BMIPP scintigraphy. BNP level increased
after RT in four patients, and mean levels of BNP at pre-
RT and post-RT were 26.32 pg/ml and 58.44 pg/ml,
respectively. One patient had ECG change after RT (fromng HT DM HL Chemotherapy RT dose
- - - CDGP + 5-FU 60 Gy/30 fr
+ - - CDGP + 5-FU 60 Gy/30 fr
- - + None 66 Gy/33 fr
- - - CDDP + 5-FU 60 Gy/30 fr
- - - CDDP + 5-FU 60 Gy/30 fr
er thoracic esophagus, Mt middle thoracic esophagus, CDGP Nedaplatin,
Figure 2 Dose volume histograms of the myocardium for 5 patients.
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had pericardial effusion after RT.
Discussion
In the present study, reduced uptake (myocardial meta-
bolic disorders) corresponding to RT fields was observed
as it was in our previous study. Although I-123 BMIPP
scintigraphy has not been used routinely compared with
myocardial perfusion scintigraphy, some studies showed
that I-123 BMIPP is superior to perfusion imaging for
evaluating the extent and severity of damage to the myo-
cardium in patients with acute and old myocardial in-
farctions [20,21]. Moreover, I-123 BMIPP scintigraphy can
be performed at rest and side effects of I-123 BMIPP scin-
tigraphy are rare. Therefore, we consider I-123 BMIPP
scintigraphy to be useful examination for detecting RT-
induced myocardial damage.Figure 3 Results of dose-effect relations for myocardial metabolic disorderAlthough reductions of fatty acid metabolism occurred
six months after RT, indicating the possibility of RT-
induced microvascular injury, Marks et al. also reported
that RT-induced myocardial perfusion defects were de-
tected six months after RT for breast cancer [8]. How-
ever, the association between early myocardial metabolic
disorders and clinically important events in the future
has been unclear. All of the patients in the present study
were asymptomatic when BMIPP scintigraphy was per-
formed. However, elevation of BNP levels in four pa-
tients and ECG change in one patient were documented,
though the association between myocardial metabolic
disorders and those cardiac examinations has also not
been clear. Previously, we also reported that there was a
significant difference between BNP values in patients
without abnormal 18F-fluorodeoxyglucose (FDG) accu-
mulation in the irradiated myocardium and those in. Dose-effect relations for reduced uptake tended to be observed.
Figure 4 Findings of single photon emission computed tomography (SPECT) in Case 5. Reduced uptake corresponding to anterior-posterior fields
was observed (red arrow). (a) pre-RT SPECT. (b) post-RT SPECT.
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esophageal cancer [22]. Based on those points, we need
to take careful note of these changes to check the pre-
sence or absence of RIHD. Because Case 5 in which re-
duced uptake corresponding to RT fields was distinct
had elevation of BNP levels, ECG change and pericardial
effusion, we intend to follow up this patient more
carefully.
Dose-effect relations for reduced uptake rate were also
observed. Hardenberg et al. evaluated dose-effect re-
gional cardiac perfusion abnormalities in patients with
left-sided breast cancer treated with RT [23]. They re-
ported that a dose-effect perfusion defect was seen at 6
months with minimal defect at 0-10 Gy, 7% decrease in
regional perfusion at 11-20 Gy, 11% decrease in regional
perfusion at 21-30 Gy, 15% decrease in regional perfu-
sion at 41-50 Gy and 20% decrease in regional perfusion
at 41-50 Gy. The pattern of dose-effect abnormalities in
their study was similar to that in our study. In an experi-
mental study by Seemann et al., mouse hearts were irra-
diated with a dose of 2, 8, or 16 Gy, and structural and
functional changes were monitored to shed light on the
dose dependence of the severity and rate of progression
of cardiovascular damage [24]. They reported that mi-
crovascular density in the left ventricle was significantly
decreased at 40 weeks after 16 Gy and that alkaline
phosphatase was significantly decreased at 40 weeksTable 2 Cardiac examinations
Case ECG (pre-RT) ECG (post-RT)
1 Left axis deviation Left axis deviation
2 Abnormal PR interval Normal
3 Normal Normal
4 Normal Normal
5 Normal T wave abnormality
Abbreviations: ECG electrocardiogram, RT radiation, BNP brain natriuretic peptide.after 2, 8 and 16 Gy. At 40 weeks, half of the hearts irra-
diated with 2 Gy and almost all of the hearts irradiated
with 8 or 16 Gy showed vascular leakage. Dose-effect
microcascular injury was also detected by pathological
examinations.
In the present study, high-dose irradiation to the myo-
cardium induced strong myocardial metabolic disorder.
Gayed et al. found that most of the myocardial perfusion
defects were encompassed within isodose lines of more
than 45 Gy using myocardial perfusion scintigraphy for
esophageal cancer [9]. In studies by Mulrooney et al.
and Schellong et al., cardiac RT dose of > 35 Gy in-
creased the incidence of cardiac disease [1,25]. One of
the risk factors of RIHD has been reported to be a high
cumulative dose of RT (>30 Gy) [26]. From visual in-
spection, reduced uptake corresponding to RT fields was
distinct in Case 4 and Case 5. V30 of the myocardium in
those cases was more than 30%. Marks et al. reported
that RT-induced myocardial perfusion defects were
correlated with the volume of irradiated myocardium
(receiving greater than 50% of prescribed dose) in pa-
tients who received a total dose of 46 to 50 Gy for left-
sided breast cancer [8]. Based on the results of those
clinical studies, we may need to make an effort to reduce
high-dose RT (>30 Gy) to the myocardium in RT plan-
ning. Because esophageal cancer and lung cancer pri-
mary are often next to heart and require larger doses forBNP (pre-RT) BNP (post-RT) Pericardial effusion
41.5 pg/ml 65.1 pg/ml +
11.0 pg/ml 20.4 pg/ml -
46.9 pg/ml 149.7 pg/ml -
24.9 pg/ml 18.8 pg/ml +
7.3 pg/ml 38.2 pg/ml +
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more carefully. A four-field technique with the combina-
tion of parallel-opposed anterior-posterior and parallel-
oblique fields may be useful to reduce the incidence of
RT-induced cardiac disease, especially in middle and
lower thoracic esophageal cancer.
In the present study, low-dose irradiation to the myocar-
dium also induced mild myocardial metabolic disorder.
The correlation between low-dose irradiation to the heart
and clinical events is not clearly known. Tukenova et al.
evaluated cardiovascular mortality after childhood cancer
[27]. They reported that the risk of cardiac disease was
significantly higher in individuals who received an average
RT dose exceeding 5 Gy (relative risk, 12.5 and 25.1 for 5
to 14.9 Gy and > 15 Gy, respectively). Mulrooney et al.
reported that cardiac RT dose of > 15 Gy increased the
relative hazards of congestive heart failure, myocardial in-
farction, pericardial disease and valvular abnormalities by
twofold to sixfold compared to non-RT survivors among
adult survivors of childhood and adolescent cancers [25].
Considering that mild microvascular injury was also de-
tected in the study by Seemann et al. [24], intensity-
modulated radiotherapy is one of the solutions to reduce
high-dose irradiation to the myocardium, but we might
also need to pay careful attention to the possibility of a
cardiac effect of low-dose mediastinal RT.
Reduced uptake was milder in Case 3 than in the other
cases in the present study. Case 3 received RT alone.
Although accurate assessment was difficult due to the
small number of cases in the present study, concomitant
chemotherapy might increase reduced uptake. Chemothe-
rapy with a platinum-based agents (cisplatin or nedaplatin)
and 5-FU was used in the present study. Some studies
showed that cisplatin was associated with cardiotoxicity
[28,29]. Cisplatin-based chemotherapy is known to be
associated with increased production of reactive oxygen
species, leading to damage of the myocardium [28].
Barjaktarovic et al. demonstrated that the level of reactive
oxygen species was enhanced in high-dose irradiated car-
diac mitochondria [30], and increased reactive oxygen
species by interaction between platinum-based agents
might have affected myocardial metabolic disorders in the
present study.
There are some limitations in the present study. First,
the number of cases was too small to analyze our results
accurately. We have since been obtaining results from
more cases. Second, there were some difficulties in regis-
tering SPECT images with RT dose distribution because
of the difference in respiratory conditions for SPECT
images at pre- and post-RT and planning CT. CT scans
were performed in the conditions of expiration for the
I-123 BMIPP examination and free breathing for the RT
planning. The regions at 50-55 Gy existed mainly in the
base of the myocardium. The base of the myocardiumwas susceptive to change in reduced uptake due to the
condition of respiration in the present study, and there
is the possibility of the degree of reduced uptake having
been underestimated or overestimated. Therefore, the
degree of reduced uptake in regions at 50-55 Gy might
have been less than that in regions at 40-45 Gy in the
present study.
Conclusions
Dose-effect relations for reduced uptake tended to be
observed. We may need to make an effort to reduce
high-dose mediastinal RT (>30 Gy) to the myocardium
in RT planning as much as possible. We will analyze
more cases and analyze dose-effect myocardial metabolic
disorders in more detail using a larger number of cases.
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